Sponsor Letter for Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd.'s Convertible Bond Issuance and Main Board Listing

Sponsor Letter

Huatai United Securities Co., Ltd. Regarding Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd.'s Convertible Bond Issuance and Main Board Listing

Shenzhen Stock Exchange:

As the sponsor for Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd. (hereinafter referred to as the "Issuer" or "Company") in its issuance of convertible bonds to unspecified investors and listing on the main board, Huatai United Securities Co., Ltd. and its sponsoring representatives have issued this sponsor letter in accordance with the Company Law of the People's Republic of China (hereinafter referred to as the "Company Law"), the Securities Law of the People's Republic of China (hereinafter referred to as the "Securities Law"), and other relevant laws and regulations, as well as the regulations of the China Securities Regulatory Commission (hereinafter referred to as the "CSRC") and your exchange. We have acted honestly and diligently, strictly following the business rules and industry self-regulatory norms established by law, and guarantee that the documents provided are true, accurate, and complete. The relevant information is reported as follows:

I. Basic Information of the Issuer

(1) Overview of the Issuer

• Issuer Name: Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd.
• Registered Address: No. 518, Yunhe Road, Xinbei District, Changzhou City
• Registration Date: April 30, 2003
• Contact Number: 0519-86020688

(2) Main Business of the Issuer

The Company is a high-tech biochemical pharmaceutical enterprise integrating R&D, production, and sales, focusing for many years on the subfields of polysaccharides and proteases, and has become a leading enterprise in this field. The main varieties of proteases include the trypsinogen series, compound digestive enzyme capsules (II), aspartic acid enzyme series, and elastase, among others. The polysaccharide varieties mainly include heparin sodium raw materials, standard heparin preparations, and low molecular weight heparin series products, with sales covering more than twenty provinces and cities across the country as well as international markets in Europe, America, and Asia. The Company is also one of the few domestic pharmaceutical manufacturers with a full traceability capability from pig intestine sources to heparin crude products, heparin raw materials, and preparations. After the operation of Henan Qianmu, it will also be one of the few heparin production enterprises in China that can trace back to the upstream pig breeding stage, which helps further ensure high-quality and controllable source quality, effectively enhancing industry competitiveness.

(3) Main Operating and Financial Data and Indicators of the Issuer

1. Consolidated Balance Sheet Main Data (Unit: Ten Thousand Yuan)

1. Consolidated Income Statement Main Data (Unit: Ten Thousand Yuan)

1. Consolidated Cash Flow Statement Main Data (Unit: Ten Thousand Yuan)